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Understanding amyloid and Alzheimer’s disease
After a century of explosive growth in the number of people affected by 
Alzheimer’s disease, there is now growing hope that the dementia can be 
better understood, recognised earlier, and ultimately cured or even prevented. 
Michael Gross reports. Grey matter: A composite image showing a healthy brain (right) and one with Alzheimer’s dis‑
ease (left) gives an impression of the changes associated with the disease. However, even the 
most sophisticated brain imaging methods available today cannot give a completely reliable 
diagnosis of Alzheimer’s disease. (Image: Sciencephotolibrary.)Just over a century ago, on the third 
of October 1910, Johann Feigl, a 
59‑year‑old day labourer from Munich, 
died after contracting pneumonia, 
after three years of suffering from 
a kind of dementia similar to that 
of Auguste Deter, whose case was 
reported at a psychiatrists’ conference 
in November 1906. For the first time 
in history, the cause of death was 
recorded as Alzheimer’s disease, after 
Alois Alzheimer (1864–1915), who 
had four years earlier described his 
investigations of Auguste Deter’s brain 
autopsy to an audience that failed to 
recognise the dawn of a new era. 
Johann Feigl was to be the first 
of many millions. With the drastic 
increase in life expectancy in the 
western world throughout the 20th 
century, Alois Alzheimer’s discovery 
rapidly gained importance and 
became one of the most serious 
medical problems of our time. In the 
UK alone there are currently 800,000 
people with dementia, and this 
number is projected to double within 
40 years. Most of them will have the 
type of dementia that Alois Alzheimer 
described, although, at the moment, 
the post‑mortem is the only reliable 
way to find out. In the autopsies of his 
patients Feigl and Deter, Alzheimer 
had observed the deposition of 
plaques between neurons, and the 
loss of brain cells leaving large gaps 
and making the brain look shrivelled. 
Later biochemical analyses showed 
that these plaques contain fibrils of 
a characteristic structure formed by 
a peptide called amyloid b, or Ab for 
short. Similar fibrils made from other 
peptides were also discovered in 
Parkinson’s disease, type 2 diabetes, 
and the prion diseases.  In the 1990s, 
researchers found that many proteins 
and peptides, including some with no 
disease association at all, were able 
to form these structures, and ‘protein 
misfolding’ became a major field of 
investigation. 
Progress in the quest to understand 
how and why these fibrils form, whether and how they cause disease 
(or whether they are just a by‑product 
of disease processes), and how 
the amyloid‑associated diseases 
can be cured or even averted may 
appear slow compared to the rapid 
increase in disease burden. However, 
significant advances have been made 
in the last decade, and a recent series 
of discoveries offers hope that the 
pace of progress is now increasing 
significantly.  
Folding and misfolding
After the discovery that many different 
proteins and peptides can form amyloid fibrils, the prevailing view was 
that their formation must start from 
a largely unfolded state, close to the 
random coil, seeing that this was the 
only conformational state that the very 
diverse proteins all had in common. 
In recent years, however, attention 
turned to intermediates much closer 
to the native state (Nat. Chem. Biol. 
(2009) 5, 15–22), which apparently can 
still turn into amyloid, suggesting that 
there are many different paths leading 
to the fibrillar structure. 
Lewis Kay and colleagues at the 
University of Toronto, in collaboration 
with Michele Vendruscolo and others 
in Cambridge, have now pinned down 
such an intermediate using a recently 
developed, highly sophisticated NMR 
approach, the Carr‑Purcell‑Meiboom‑
Gill (CPMG) relaxation dispersion 
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Tangled: Deposits of amyloid fibrils are found 
in association with a number of diseases, 
including Alzheimer’s, Parkinson’s and type 
2 diabetes. This picture of an insulin fibril 
shows a model of the characteristic cross‑
beta structure fitted into the envelope of the 
fibril shape as determined by cryo‑electron 
microscopy. (Image: Helen Saibil, Birkbeck 
College London.)
Toxic molecules: The hunt for the molecular 
species that actually cause the brain damage 
observed in Alzheimer’s disease is currently 
focusing on amyloid oligomers, i.e. complex‑
es of only around half a dozen peptide mol‑
ecules. The image shows one of the crystal 
structures of amyloid oligomers determined 
by David Eisenberg’s group. (Image: Protein 
Data Bank: PDB access code 3SGM.)method, which makes it possible to 
study protein folding reactions on the 
millisecond timescale and at atomic 
resolution. With this approach, the 
researchers were able to characterise 
a folding intermediate of the well‑
characterised SH3 domain that is 
populated only by 2% of the protein 
molecules in the NMR sample at 
a given time (Science (2012), 336, 
362–366). 
Kay’s team could show that in this 
fleetingly present intermediate the carboxyl terminus of the polypeptide 
chain hasn’t yet found its place 
and thus remains unstructured. 
This, the researchers suspected, 
leaves the area of the structure 
where the carboxyl terminus should 
normally dock — the edge of an 
incomplete beta sheet — vulnerable 
to aggregation and possibly to 
amyloid formation. To test for this 
possibility, they produced a mutant 
protein lacking the unstructured tail 
of the intermediate, and found that it 
does indeed form amyloid much more 
readily than the full‑length protein. 
Why didn’t the intermediate 
aggregate out as amyloid in their 
previous experiment? The reason is 
likely to be the very low population — 
as only 2% of the molecules adopt 
this structure at a given time, they 
have a much reduced probability of 
bumping into other aggregation‑prone 
molecules and reacting with them. 
While the molecular details of this 
case may or may not be generalisable 
to other amyloid‑forming proteins, 
it is noteworthy and likely to be of 
general importance that a near‑
native intermediate can still be highly 
amyloidogenic and is only prevented 
from forming amyloid fibrils by being 
highly diluted amongst more stable 
forms of the protein.
“This is an exciting approach to 
studying protein folding reactions, 
because it allows us to catch a 
fleeting glimpse of proteins at their 
most vulnerable,” says biophysicist 
Cait McPhee from the University of 
Edinburgh. “And it’s surprising and 
perhaps a little disturbing that such a 
small, apparently insignificant change 
is sufficient to tip the balance between 
a well‑behaved protein and one that 
is prone to aggregation. Up until now 
we’ve assumed some fairly drastic 
structural rearrangements were 
required — but it now appears that’s 
not the case.”
But will it help at the medical 
front? Chris Dobson from the 
University of Cambridge is 
optimistic: “The development of an 
array of increasingly sophisticated 
biophysical techniques, such as 
that used by Lewis Kay and his 
colleagues, is now proceeding very 
rapidly and is transforming our 
ability to define in exquisite detail 
the molecular steps involved in the 
process of amyloid formation by 
specific proteins,” he commented. 
“With this information it is becoming possible not just to understand 
the molecular origins of misfolding 
diseases but to use this information 
for the rational design of therapeutic 
strategies to combat these 
devastating diseases.”
Cause or symptom?
A long‑running debate in the field 
concerns the question whether the 
amyloid fibrils are ultimately the cause 
of the brain damage in Alzheimer’s 
disease or whether they are just 
a side‑effect produced by as yet 
unresolved underlying mechanisms 
that lead to neuronal death. In recent 
years, attention has shifted away 
from the full‑length fibrils and towards 
smaller units, so called amyloid 
oligomers, which have been found to 
be more cytotoxic than the mature 
fibres. They may only contain half a 
dozen protein molecules, but they 
do show specific structural elements 
distinct from both the protein 
monomers and the full amyloid fibrils. 
There are, for instance, antibodies that 
specifically recognise the oligomers, 
but neither the monomers nor the 
fibrils. 
The group of David Eisenberg at 
the University of California at Los 
Angeles has recently reported the 
crystal structure of such a cytotoxic 
amyloid oligomer, derived from the 
eye lens chaperone aB crystallin 
(Science (2012), 335, 1228–1231). 
The structural unit is a small barrel of 
six antiparallel b strands, which they 
called a cylindrin. 
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Smart move: A large number of epidemiological studies suggests that keeping one’s brain 
exercised may help to avert dementia. (Photo: GettyImage.)The antiparallel b sheets in the 
barrel are staggered with respect 
to the neighbouring sheets (‘out 
of register’) while the structures of 
full‑length fibrils show neatly lined up 
beta sheets (‘in register’) all the way 
through. Thus there is no quick and 
easy way of converting the cylindrin 
structure into the fibril structure, and 
many hydrogen bonds would have to 
be broken to achieve this conversion. 
Eisenberg and colleagues conclude 
that the cylindrin is probably not an 
intermediate on the pathway leading 
to full‑length fibrils. 
The researchers also admit that 
their “cylindrin may represent one 
of many possible assemblies of 
cylindrin‑like structures.” Thus, the 
number of peptides per oligomer and 
the dislocation between neighbouring 
strands may be variable and produce 
a wide variety of structurally different 
complexes. Which of these are 
medically relevant remains to be 
explored. 
In another recent development, 
David Klenerman’s and Chris 
Dobson’s groups in Cambridge have 
shown that misfolding results in a 
wide distribution of toxic oligomers, 
using single‑molecule techniques that 
enable the researchers to observe and
begin to characterise the oligomers 
(Nat. Struct. Mol. Biol. (2012) 19, 
79–83). “Our paper also shows that 
the extracellular chaperone clusterin 
sequesters these oligomers and 
hence provides important clues as to 
how our natural defences function,” 
Dobson told Current Biology.
Diagnosis and therapy
Initially, the hallmark brain changes 
distinguishing Alzheimer’s disease 
from other kinds of dementia could 
only be detected post mortem in 
a brain autopsy. Brain imaging 
methods like magnetic resonance 
imaging (MRI), positron emission 
tomography (PET) and single photon 
emission computed tomography 
(SPECT) have provided some help, 
but experts still estimate that one 
in five patients diagnosed with 
Alzheimer’s while they were alive 
failed to display the characteristic 
symptoms on autopsy. 
Only in April this year did the 
US Food and Drug Administration 
(FDA) approve the first substance 
for a diagnostic test that can detect 
plaques in the living brain. The test 
developed by the company Eli Lilly is based on a radioactively (fluorine‑19) 
labelled compound called florbetapir 
(product name: Amyvid), which 
binds to amyloid plaques and can be 
detected in PET scans. 
Making a diagnosis based on these 
scans is far from easy, however. A 
previous application from Eli Lilly 
was turned down by the FDA on the 
grounds that the training the company 
provided for the interpretation of 
the scans was insufficient. Still, 
even a specially trained doctor may 
get the result wrong, and the best 
diagnoses were obtained in a study 
where each scan was read by five 
people and the majority vote decided 
the verdict. 
And even with training and controls 
in place, the company admits in its 
product information that “a positive 
Amyvid scan does not establish a 
diagnosis of Alzheimer’s disease, or 
other cognitive disorder.” 
Commenting on the announced FDA 
approval for Amyvid, which failed to 
translate into a rise in share prices 
for the company, Matthew Herper of 
Forbes magazine wrote that, while the 
method has little benefit for people 
actually suffering from Alzheimer’s, it 
is useful to rule out the possibility in 
those who don’t. “If drug companies 
can screen out patients who are likely 
not to have Alzheimer’s, they are far 
more likely to be able to show that 
medicines aimed at Alzheimer’s are 
effective in clinical trials. Having those 
non‑Alzheimer’s patients in a study is going to wash out the efficacy of a 
new drug,” Herper writes, concluding: 
“This really is a clever move by Lilly to 
make some profit on a research tool.”
The other reason why diagnostic 
tools aren’t much use for the patients 
right now is the fact that there is no 
therapeutic intervention that actually 
stops the progress of the disease, 
let alone restores the healthy brain. 
All drugs available for Alzheimer’s 
patients so far can alleviate symptoms 
but can neither stop nor cure the 
disease. What could a successful 
therapy look like? A recent study with 
an animal model offers a glimpse of a 
better future. 
The group of Gary Landreth at 
the Case Western University at 
Cleveland (Ohio, US) has recently 
reported a very promising study 
showing that a drug that is already 
approved for other diseases can 
clear soluble amyloid and plaques 
and restore cognitive functions in a 
mouse model of Alzheimer’s disease 
(Science (2012), 335, 1503–1506). 
The miracle compound is betaroxene 
(Targretin), a substance that can 
permeate the blood–brain barrier and 
activates retinoid X receptors (RXRs). 
These membrane proteins form 
dimers with other receptors known 
to upregulate the activity of the apoE 
gene, resulting in the production of 
apolipoprotein E. This lipoprotein 
helps the formation of high density 
lipoprotein (HDL) particles, which 
in turn speed up the digestion and 
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Two years on, the national spotlight 
seems to have turned away from 
the Gulf oil spill, but a massive 
assessment of the environmental 
impacts is quietly under way. As 
Cyrus Martin reports, several 
recent observations, and a study 
of deepwater coral communities, 
suggest we may not be out of the 
woods yet.
Friday April 20th marked the second 
anniversary of the US’s largest ever 
oil spill, which began when the 
Deepwater Horizon oil rig experienced 
a blowout and explosion while drilling 
off the coast of Louisiana. Eleven 
men died in the explosion, which 
resulted in a gushing wellhead many 
thousands of feet below the surface 
that for months frustrated attempts to 
plug it. When the Macondo well was 
finally capped, nearly 5 million gallons 
of ‘sweet’ crude had been injected 
into the seawater at great depth, 
some of it surfacing and infiltrating 
the coast. At the time, the spill had 
acute effects on the economies of the 
Gulf states, as many local fishermen 
were forced to keep their boats in 
dock when leaked crude inevitably 
contaminated their fisheries. And the 
tourism industry took a big hit as the 
spill unfortunately coincided with the 
peak of the season. 
Just last month, BP, the operator 
of the well, agreed in court to pay 
$7.8 billion in claims to the aggrieved 
parties — at least 100,000 plaintiffs. 
And these were just the claims from 
private individuals; the government 
itself is likely to extract more in future 
litigation. For example, a stipulation 
in the Clean Water Act requires that 
BP pay a fine based on the amount of 
oil spilled, fines that are estimated to 
exceed $3 billion. Ideally, this money 
would be funnelled back to the Gulf 
states themselves but legislation 
introduced in Congress known as the 
Restore Act has yet to be approved by 
both houses.
The total amount of money wrung 
from BP’s pockets will depend 
on an ongoing assessment of the 
environmental impact in the Gulf 
stemming from the leak, and the steps 
needed to repair the damage. This 
begs the question: what, if anything, 
has happened to the Gulf coast’s 
ecosystems? Coincidentally, Earth 
Day follows close on the heels of the 
spill anniversary, giving even more 
reason to reassess the environmental 
impacts.
In the immediate aftermath of the 
leak, it was clear that the effects 
of the spill would be far‑reaching. 
Local residents stepped out on their 
beaches to see their shoreline awash 
in oil. An initial survey of 4,300 miles 
of coast found 1,100 miles of oiled 
shoreline, 220 miles heavily so. As 
in the case of the Valdez disaster, 
the plight of the most conspicuous 
wildlife was center stage. Rescue 
volunteers and news media, fanning 
out to assess the impacts of the spill, 
were confronted with dead or dying 
waterfowl, and sea turtles greased 
with petroleum. There was wide 
speculation that we were reliving 
Valdez, but on a much larger scale.
Fast forward to today, by contrast, 
and the Gulf seems to be back in 
business. Locals and tourists alike 
flock to the beaches and are by 
and large greeted by the pristine 
beauty of the Gulf just as it was. And 
by all accounts, most of the fisheries 
are seeing productivity comparable 
to pre‑spill times. But there have 
been several ominous events in the 
aftermath of the spill that suggest 
something sinister may be lurking in 
the shadows. For one, the beaches 
aren’t quite as immaculate as BP’s 
public relations campaign would 
indicate. Unsightly tar balls do still 
wash ashore, and there are many 
wetlands where, if you use an oar 
to poke through the marsh grass, 
a dark sludge is revealed. Perhaps 
the most portentous sign has been 
a spate of dolphin beachings up and 
down the Gulf coast. According to the 
National Oceanic and Atmospheric 
Administration (NOAA), 75 
dolphins a year on average beach 
themselves along the Gulf coast, but 
since February, 2010, the region has 
witnessed 675 beached dolphins, 
many of them with low body weight, 
anemia, hypoglycemia, and liver and 
lung disease. Many of the dolphins 
are also infected with the bacterium 
Brucella, but so far there have been 
no conclusive links between these 
symptoms, the pathogen, and the 
oil spill itself. Further clouding these 
events, NOAA is reporting that the 
dolphin beachings started to increase 
before the Macondo wellhead ever 
Gulf spill two years 
outclearance of soluble Ab. Mutations in 
the apoE gene are the most common 
genetic defect associated with 
sporadic Alzheimer’s, thus activation 
of the gene is considered to be a 
promising approach. 
Landreth and colleagues found 
that oral administration of bexarotene 
resulted in improved clearance of 
soluble Ab within a few hours, due 
to enhanced apoE activity. They also 
found that the area affected by Ab 
plaques was reduced by half within 
three days. Most encouragingly, the 
mice regained cognitive, social, and 
olfactory abilities they had already 
lost to the disease. 
The UK’s Alzheimer’s Society 
welcomed the news with cautious 
enthusiasm: “This exciting study 
could be the beginning of a journey 
towards a potential new way to treat 
Alzheimer’s disease,” commented 
Anne Corbett, research manager for 
the society. She cautioned: “However, 
this is very early days. People with 
Alzheimer’s should not rush to get 
this drug, as we need much more 
research to establish if it has benefits 
for humans.” 
More generally, the Alzheimer’s 
Society sees hope in the approach 
of finding Alzheimer drugs among 
the substances already approved for 
other applications. “Investigating the 
added benefits of existing licensed 
drugs is an innovative approach 
in our fight against the condition, 
and one which Alzheimer’s Society 
is championing through its drug 
discovery programme. This could 
see new treatments for dementia 
being developed much sooner,” the 
statement said. 
As more and more people are 
reaching the age where Alzheimer’s 
disease becomes a dominant health 
risk, the need for real treatment 
options is getting more urgent. Alois 
Alzheimer, however, did not live 
long enough to get ‘his’ disease. In 
December 1915, just a few years 
after his name became attached 
to the dementia, he succumbed 
to complications after contracting 
an infectious disease aged 51, 
a fairly normal fate in a bygone 
world without antibiotics, where 
only academic psychiatrists knew 
about Alzheimer’s disease.
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
page at www.michaelgross.co.uk
